...
首页> 外文期刊>Diabetes care >Significance of urinary full-length and ectodomain forms of megalin in patients with type 2 diabetes.
【24h】

Significance of urinary full-length and ectodomain forms of megalin in patients with type 2 diabetes.

机译:尿蛋白全长和胞外域形式的巨蛋白在2型糖尿病患者中的意义。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVE Megalin, an endocytic receptor in proximal tubule cells, is involved in the mechanisms of albuminuria in diabetic nephropathy (DN). To develop efficient novel biomarkers associated with the pathogenesis of DN, we investigated urinary megalin excretion in type 2 diabetes. RESEARCH DESIGN AND METHODS Sandwich enzyme-linked immunosorbent assay systems were established with monoclonal antibodies against the NH(2) (amino [A]-megalin assay) and COOH (C-megalin assay) termini of megalin to analyze urinary forms of megalin in 68 patients with type 2 diabetes. RESULTS The A-megalin assay mainly detected a megalin ectodomain form in the soluble urinary fraction, whereas the C-megalin assay identified a full-length form in both soluble and insoluble fractions. Urinary C-megalin levels were significantly high in patients with normoalbuminuria, were elevated in line with increased albuminuria, and showed a better association with estimated glomerular filtration rate (eGFR) (<60 mL/min/1.73 m(2)) than did urinary albumin. In contrast, urinary A-megalin levels were increased in patients with normo- and microalbuminuria but not in those with macroalbuminuria. Urinary C-megalin levels were also positively associated with plasma inorganic phosphate and negatively with hemoglobin levels in those showing no features of bleeding and not taking vitamin D analogs, phosphate binders, or erythropoiesis-stimulating agents. CONCLUSIONS Urinary full-length megalin excretion as measured by the C-megalin assay is well associated with reduced eGFR and linked to the severity of DN, phosphate dysregulation, and anemia, whereas urinary excretion of megalin ectodomain as measured by the A-megalin assay may be associated with distinctive mechanisms of earlier DN in type 2 diabetes.
机译:目的Megalin是近端肾小管细胞中的一种胞吞受体,参与糖尿病性肾病(DN)的蛋白尿机制。为了开发与DN的发病机制相关的有效的新型生物标志物,我们研究了2型糖尿病中尿巨蛋白的排泄。研究设计与方法建立了夹心酶联免疫吸附测定系统,该系统使用针对megalin的NH(2)(氨基[A] -megalin测定)和COOH(C-megalin测定)末端的单克隆抗体来分析megalin中尿液的形式2型糖尿病患者。结果A-巨蛋白测定主要检测可溶性尿部分中的巨蛋白胞外域形式,而C-巨蛋白测定则确定可溶性和不溶部分中的全长形式。正常白蛋白尿患者的尿C-巨蛋白水平显着较高,与白蛋白尿增加一致,并且与估计的肾小球滤过率(eGFR)(<60 mL / min / 1.73 m(2))关联更好白蛋白。相反,常白蛋白尿和微量白蛋白尿的患者尿中A-巨蛋白水平升高,而大白蛋白尿的患者则没有。在没有出血特征且不服用维生素D类似物,磷酸盐结合剂或促红细胞生成剂的患者中,尿C-巨蛋白水平与血浆无机磷酸盐呈正相关,与血红蛋白水平呈负相关。结论:通过C-megalin分析测定的尿液全长megalin排泄与eGFR降低密切相关,并与DN的严重程度,磷酸盐失调和贫血有关,而通过A-megalin分析测定的megalin胞外域尿排泄可能与2型糖尿病早期DN的独特机制相关。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号